Abstract: Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly used for the prevention of cardiovascular diseases associated with dyslipidemia. The main adverse reaction of statins is muscle toxicity, which may induce skeletal muscle-related symptoms, including mild myalgia and severe rhabdomyolysis. This paper summarizes the advances in the studies of statin-induced muscle symptoms based on recent literature on epidemiology, clinical features, mechanism of action, and treatment of statin-associated muscle symptoms, so as to provide evidence for clinical safety and further studies of statins.